Trial Profile
A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposide.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Pixantrone (Primary) ; Etoposide; Ifosfamide; Rituximab
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms PIVeR
- 25 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2018 New trial record